Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Slifstein

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Journal of Labelled Compounds & Radiopharmaceuticals|May 15, 2026
Fully Automated Production of Multiple <sup>11</sup>C-Labeled PET Tracers Using a Self-Cleaning TracerMaker RadiosynthesizerBao Hu, Wenchao Qu, Ramin Parsey, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 7, 2005
Effect of spatial smoothing on t-maps: arguments for going back from t-maps to masked contrast imagesMatthias Reimold, Mark Slifstein, Andreas Heinz, et al.
Physics in Medicine and Biology|October 30, 2015
Quantitative imaging of protein targets in the human brain with PETRoger N Gunn, Mark Slifstein, Graham E Searle, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 10, 2009
Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visitedVincent J Cunningham, Eugenii A Rabiner, Mark Slifstein, et al.
Drug and Alcohol Dependence|August 11, 2014
Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictorsSean X Luo, Diana Martinez, Kenneth M Carpenter, et al.
Biological Psychiatry|January 27, 2009
Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjectsAnissa Abi-Dargham, Elsmarieke van de Giessen, Mark Slifstein, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 24, 2010
Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] racloprideMark Slifstein, Raymond F Suckow, Jonathan A Javitch, et al.
Psychopharmacology|March 6, 2013
In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophreniaEline M P Poels, Ragy R Girgis, Judy L Thompson, et al.
Biological Psychiatry|May 22, 2016
Pathway-Specific Dopamine Abnormalities in SchizophreniaJodi J Weinstein, Muhammad O Chohan, Mark Slifstein, et al.
Archives of General Psychiatry|April 5, 2012
The nature of dopamine dysfunction in schizophrenia and what this means for treatmentOliver D Howes, Joseph Kambeitz, Euitae Kim, et al.
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Journal of Labelled Compounds & Radiopharmaceuticals|May 15, 2026
Fully Automated Production of Multiple <sup>11</sup>C-Labeled PET Tracers Using a Self-Cleaning TracerMaker RadiosynthesizerBao Hu, Wenchao Qu, Ramin Parsey, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 7, 2005
Effect of spatial smoothing on t-maps: arguments for going back from t-maps to masked contrast imagesMatthias Reimold, Mark Slifstein, Andreas Heinz, et al.
Physics in Medicine and Biology|October 30, 2015
Quantitative imaging of protein targets in the human brain with PETRoger N Gunn, Mark Slifstein, Graham E Searle, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 10, 2009
Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visitedVincent J Cunningham, Eugenii A Rabiner, Mark Slifstein, et al.
Drug and Alcohol Dependence|August 11, 2014
Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictorsSean X Luo, Diana Martinez, Kenneth M Carpenter, et al.
Biological Psychiatry|January 27, 2009
Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjectsAnissa Abi-Dargham, Elsmarieke van de Giessen, Mark Slifstein, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 24, 2010
Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] racloprideMark Slifstein, Raymond F Suckow, Jonathan A Javitch, et al.
Psychopharmacology|March 6, 2013
In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophreniaEline M P Poels, Ragy R Girgis, Judy L Thompson, et al.
Biological Psychiatry|May 22, 2016
Pathway-Specific Dopamine Abnormalities in SchizophreniaJodi J Weinstein, Muhammad O Chohan, Mark Slifstein, et al.
Archives of General Psychiatry|April 5, 2012
The nature of dopamine dysfunction in schizophrenia and what this means for treatmentOliver D Howes, Joseph Kambeitz, Euitae Kim, et al.
Pageof 14